Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation ...
Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million- driven by growth in MIPLYFFA net revenue to $87.4 million 2025 EPS of $1.40 basic ...
This article examines how cultivated fat has the potential to bridge the gap between plant-based analogs and authentic animal tissue.
Background Gut bacteria have been implicated in a wide range of health conditions, yet their potential role in preventing and treating muscle-wasting disorders remains largely unexplored. Objective We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results